Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study

被引:31
|
作者
Mundwiler, Matthew L. [2 ]
Mei, Ling [1 ]
Landers, Carol J. [1 ]
Reveille, John D. [3 ]
Targan, Stephan [1 ]
Weisman, Michael H. [1 ]
机构
[1] Cedars Sinai Med Ctr, Ctr Inflammatory Bowel Dis, Los Angeles, CA 90048 USA
[2] Rockford Orthoped Associates, Rockford, IL 61107 USA
[3] Univ Texas Hlth Sci Ctr, Houston, TX 77030 USA
关键词
CROHNS-DISEASE; SACCHAROMYCES-CEREVISIAE; MICROBIAL ANTIGENS; PSOAS COHORT; ANTIBODIES; ASSOCIATION; PREVALENCE; SPONDYLOARTHROPATHIES; AUTOANTIBODIES; ARTHRITIS;
D O I
10.1186/ar2866
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) share similarities and are classified as spondyloarthropathies. In IBD, anti-Saccharomyces cerevisiae antibody (ASCA), anti-I2 (associated with anti-Pseudomonas activity), anti-Escherichia coli outer membrane porin C (anti-OmpC), anti-flagellin (anti-CBir1), and antineutrophil cytoplasmic antibodies (ANCA) possess clinical significance. Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls. Methods Serum stored from 80 AS patients and 80 control subjects was available for analysis. ASCA, anti-I2, anti-OmpC, anti-CBir1, and ANCA studies were completed on all serum samples using Enzyme-Linked Immunosorbent Assay (ELISA) methodology. The following analyses were performed: comparison of positivity based on the established values in IBD, median values, the number of subjects in each serology in the 4(th) quartile of a normal distribution, and the mean quartile sum of all the antibodies. Results There was no difference in positivity rates between AS and control groups with the established IBD values. The median anti-I2 response was significantly higher in AS than in controls (11.78 vs 7.86, p = 0.017). Significantly more AS patients had quartile scores of 4 for the following antibody responses: ASCA IgG (26% vs 13%, p = 0.016, OR = 2.49, CI 1.168-5.313), ASCA IgG and IgA (27% vs 12%, p = 0.006, OR = 2.9, CI: 1.342-6.264), and anti-I2 (25% vs 14%, p = 0.0424, OR = 2.15, CI: 1.018-4.538). The mean quartile sum of the antibody responses was elevated in AS patients when ANCA was excluded (10.526 vs 9.519, p = 0.03). When ANCA was included, this difference lost significance. Conclusions The data from this pilot study points towards mucosal dysregulation as an important pathway in AS. We were able to demonstrate that anti-I2 could play a pathologic role in AS. The elevated mean total antibody response being significant only with ANCA exclusion is consistent with the histopathological evidence that intestinal inflammation in AS is similar to Crohn's disease. To better define the roles of these antibodies in AS, larger studies with more precisely defined patient characteristics are required.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Ankylosing spondylitis and bowel disease
    Rudwaleit, Martin
    Baeten, Dominique
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (03): : 451 - 471
  • [22] pANCA, ASCA, and OmpC Antibodies in Patients with Ankylosing Spondylitis without Inflammatory Bowel Disease
    de Vries, Miriam
    van der Horst-Bruinsma, Irene
    van Hoogstraten, Ingrid
    van Bodegraven, Adriaan
    von Blomberg, Mary
    Ratnawati, Hana
    Djkmans, Ben
    JOURNAL OF RHEUMATOLOGY, 2010, 37 (11) : 2340 - 2344
  • [23] Secukinumab as a potential trigger of inflammatory bowel disease in ankylosing spondylitis or psoriatic arthritis patients
    Onac, Ioana A.
    Clarke, Benjamin D.
    Tacu, Cristina
    Lloyd, Mark
    Hajela, Vijay
    Batty, Thomas
    Thoroughgood, Jamie
    Smith, Sandra
    Irvine, Hannah
    Hill, Diane
    Baxter, Grace
    Horwood, Natalie
    Mahendrakar, Suma
    Rajak, Rizwan
    Griffith, Sian
    Kiely, Patrick D. W.
    Galloway, James
    RHEUMATOLOGY, 2021, 60 (11) : 5233 - 5238
  • [24] A common genetic background for inflammatory bowel disease and ankylosing spondylitis -: A genealogic study in Iceland
    Thjodleifsson, Bjarni
    Geirsson, Arni J.
    Bjornsson, Sigurdur
    Bjarnason, Ingvar
    ARTHRITIS AND RHEUMATISM, 2007, 56 (08): : 2633 - 2639
  • [25] Exploring the Link Between Ankylosing Spondylitis and Inflammatory Bowel Disease: A Retrospective Cohort Study
    Sharif, Kassem
    Lahat, Adi
    Shneor, Yonatan
    Ben-Shabat, Niv
    Omar, Mahmud
    Watad, Abdulla
    Amital, Howard
    Gendelman, Omer
    ISRAEL MEDICAL ASSOCIATION JOURNAL, 2024, 26 (04): : 226 - 231
  • [26] Disease severity in Ankylosing Spondylitis: The influence of associated inflammatory bowel disease and psoriasis
    Bradbury, L.
    Lewington, M.
    Warner, J.
    Farrar, C.
    Wordsworth, B. P.
    Brown, M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (04) : 751 - 751
  • [27] COEXISTING INFLAMMATORY BOWEL DISEASE AND ANKYLOSING SPONDYLITIS: MANAGEMENT AND CLINICAL OUTCOMES
    Savin, E.
    Gendelman, O.
    Levartovsky, A.
    Lidar, M.
    Amital, H.
    Ben-Horin, S.
    Kopylov, U.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1692 - 1693
  • [28] PREVALENCE OF OCCULT INFLAMMATORY BOWEL-DISEASE IN ANKYLOSING-SPONDYLITIS
    COSTELLO, PB
    ALEA, JA
    KENNEDY, AC
    MCCLUSKEY, RT
    GREEN, FA
    ANNALS OF THE RHEUMATIC DISEASES, 1980, 39 (05) : 453 - 456
  • [29] Thoracic Manifestations of Ankylosing Spondylitis, Inflammatory Bowel Disease, and Relapsing Polychondritis
    Danve, Abhijeet
    CLINICS IN CHEST MEDICINE, 2019, 40 (03) : 599 - +
  • [30] Coexisting Inflammatory bowel disease and Ankylosing spondylitis: Management and clinical outcomes
    Savin, E.
    Levartovsky, A.
    Gendelman, O.
    Lidar, M.
    Ben-Horin, S.
    Kopylov, U.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 698 - 698